Imaging Biometrics, LLC (IB), a subsidiary of IQ-AI Limited and a recognized leader in quantitative imaging analysis for brain tumor diagnosis and treatment, today announced that the MRI DSC perfusion technology, first made commercially available in IB Neuro, earned recognition as the national standard for use in high-grade brain tumors.

June 19, 2020 — Imaging Biometrics, LLC (IB), a subsidiary of IQ-AI Limited and a recognized leader in quantitative imaging analysis for brain tumor diagnosis and treatment, today announced that the MRI DSC perfusion technology, first made commercially available in IB Neuro, earned recognition as the national standard for use in high-grade brain tumors. This recognition was the outcome of the DSC-MRI Standardization Subcommittee of the Jumpstarting Brain Tumor Drug Development Coalition. The Committee’s findings, published in Neuro Oncology (Consensus Recommendations for a DSC MRI Protocol), provide evidence-based best practices for routine clinical use from both an MR acquisition and post-processing perspective. DSC, which stands for dynamic susceptibility contrast, is the most common perfusion MRI technology used for the evaluation of brain tumors.

This national consensus is long overdue. Despite its widespread use, MRI-DSC imaging has been plagued by inconsistent and suboptimal ways of acquiring and processing DSC-MRI data resulting in mixed opinions regarding its usefulness. Instead, IB Neuro has been honed and developed, over two decades, to account for subtle nuances in data acquisition and post-processing. It is the only MRI-DSC platform that offers truly quantitative output regardless of scanner platform, field strength, or time point and is the only commercial platform validated with tissue biopsy samples by multiple institutions. More recently, a low contrast agent dosing scheme was validated using IB Neuro. This reduced contrast alternative provides excellent agreement with the accepted double-dose protocol and is being adopted by more and more sites.

Michael Schmainda, CEO of IB, added, “We continue to advance our understanding and application in MRI-DSC imaging, and IB Neuro is foundational in that regard. The automated and quantitative processing in IB Neuro is also the default standard for the National Clinical Trials Network and is widely available for routine clinical use.”

For more information: www.imagingbiometrics.com


Related Content

News | Artificial Intelligence

March 1, 2024 — Royal Philips, a global leader in health technology, and magnetic resonance imaging (MRI) software ...

Time March 01, 2024
arrow
News | FDA

March 1, 2024 — Varian, a Siemens Healthineers company, announced that it has received 510(k) clearance from the U.S ...

Time March 01, 2024
arrow
News | HIMSS

February 29, 2024 — The Healthcare Information Management Systems Society, HIMSS, recently announced it HIMSS 2024 ...

Time February 29, 2024
arrow
News | Cardiac Imaging

February 28, 2024 — Royal Philips, a global leader in health technology, announced major enhancements to its Image ...

Time February 28, 2024
arrow
News | Magnetic Resonance Imaging (MRI)

February 28, 2024 — Royal Philips, a global leader in health technology, today announced a significant milestone as it ...

Time February 28, 2024
arrow
News | Artificial Intelligence

February 28, 2024 — DeepHealth, one of the leading providers of radiology informatics and AI solutions, and Incepto ...

Time February 28, 2024
arrow
News | Radiology Business

February 28, 2024 — Royal Philips has announced the proposal to appoint Charlotte Hanneman as member of the Board of ...

Time February 28, 2024
arrow
News | Artificial Intelligence

February 27, 2024 — As artificial intelligence (AI) is increasingly used in radiology, researchers caution that it’s ...

Time February 27, 2024
arrow
News | X-Ray

February 26, 2024 — AIxSCAN, Inc. began clinical trials in late 2023. The AIxSCAN, Inc. team is very pleased with the ...

Time February 26, 2024
arrow
News | Enterprise Imaging

February 26, 2024 — Hyland Healthcare, a leading global provider of intelligent content and enterprise imaging solutions ...

Time February 26, 2024
arrow
Subscribe Now